DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
MIFAMURTIDE
2
Small molecule
Investigational
Unknown
Unknown
Osteosarcoma
Nucleotide-binding oligomerization domain-containing protein 2 other
MIFAMURTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
1LM890Q4FY
Molecule Type:
Small molecule
Molecular Formula:
C59H109N6O19P
Molecular Weight:
1237.52
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MYRCLUDEX B
2
Unknown
Investigational
Unknown
Unknown
Hepatitis B, Chronic; Hepatitis D
Unknown
MYRCLUDEX B
×
Maximum Phase:
2
First Approval:
None
UNII:
JA8K50N04H
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CASTOR OIL
2
Small molecule
Investigational
Unknown
Unknown
Premature Birth; Constipation
Unknown
CASTOR OIL
×
Maximum Phase:
2
First Approval:
None
UNII:
D5340Y2I9G
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ADU-S100
2
Unknown
Investigational
Unknown
Unknown
Lymphoma; Head and Neck Neoplasms
Stimulator of interferon genes protein agonist
ADU-S100
×
Maximum Phase:
2
First Approval:
None
UNII:
FMW9ZVF53N
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUJ591 177LU
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
HUJ591 177LU
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TIPLIMOTIDE
2
Protein
Investigational
Unknown
Unknown
Multiple Sclerosis
Unknown
TIPLIMOTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
6VN101530Y
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VALEMETOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VALEMETOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
60RD0234VE
Molecule Type:
Small molecule
Molecular Formula:
C26H34ClN3O4
Molecular Weight:
488.03
AlogP:
4.49
PSA:
83.66
HBD:
2.0
HBA:
#RotB:
5.0
Source:
CERAMIDE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Leukemia, Myeloid, Acute; Breast Neoplasms
Unknown
CERAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
ZZK8X1CR0R
Molecule Type:
Small molecule
Molecular Formula:
C20H41NO3
Molecular Weight:
343.55
AlogP:
4.33
PSA:
69.56
HBD:
3.0
HBA:
#RotB:
17.0
Source:
PIXANTRONE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms
DNA cross-linking agent
PIXANTRONE
×
Maximum Phase:
2
First Approval:
None
UNII:
F5SXN2KNMR
Molecule Type:
Small molecule
Molecular Formula:
C17H19N5O2
Molecular Weight:
325.37
AlogP:
0.6
PSA:
123.13
HBD:
4.0
HBA:
#RotB:
6.0
Source:
ULODESINE
2
Small molecule
Investigational
Unknown
Unknown
Gout; Hyperuricemia; Osteoarthritis
Unknown
ULODESINE
×
Maximum Phase:
2
First Approval:
None
UNII:
JNG8L9460Y
Molecule Type:
Small molecule
Molecular Formula:
C12H16N4O3
Molecular Weight:
264.29
AlogP:
-0.96
PSA:
105.24
HBD:
4.0
HBA:
#RotB:
3.0
Source:
EDAP
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
EDAP
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CP-195543
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Leukotriene B4 receptor antagonist
CP-195543
×
Maximum Phase:
2
First Approval:
None
UNII:
YB1F0V77MK
Molecule Type:
Small molecule
Molecular Formula:
C24H19F3O4
Molecular Weight:
428.41
AlogP:
5.36
PSA:
66.76
HBD:
2.0
HBA:
#RotB:
4.0
Source:
BUTYLATED HYDROXYTOLUENE
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
Unknown
BUTYLATED HYDROXYTOLUENE
×
Maximum Phase:
2
First Approval:
None
UNII:
1P9D0Z171K
Molecule Type:
Small molecule
Molecular Formula:
C15H24O
Molecular Weight:
220.36
AlogP:
4.3
PSA:
20.23
HBD:
1.0
HBA:
#RotB:
0.0
Source:
PG-530742
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis, Knee
Unknown
PG-530742
×
Maximum Phase:
2
First Approval:
None
UNII:
F94T42GL80
Molecule Type:
Small molecule
Molecular Formula:
C24H27N3O7S
Molecular Weight:
501.56
AlogP:
1.4
PSA:
134.27
HBD:
3.0
HBA:
#RotB:
9.0
Source:
BROSTALLICIN
2
Small molecule
Investigational
Unknown
Unknown
Multiple Myeloma; Liposarcoma, Myxoid; Triple Negative Breast Neoplasms
DNA disrupting agent
BROSTALLICIN
×
Maximum Phase:
2
First Approval:
None
UNII:
RPC6R41K4I
Molecule Type:
Small molecule
Molecular Formula:
C30H35BrN12O5
Molecular Weight:
723.59
AlogP:
1.65
PSA:
229.62
HBD:
7.0
HBA:
#RotB:
12.0
Source:
ONZIGOLIDE
2
Unknown
Investigational
Unknown
Unknown
Pituitary Neoplasms
Unknown
ONZIGOLIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
C86H116N16O12S4
Molecular Weight:
1694.24
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
IRX-2
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Breast Neoplasms; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Squamous Intraepithelial Lesions
Unknown
IRX-2
×
Maximum Phase:
2
First Approval:
None
UNII:
ZDR4QSJ43F
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DILMAPIMOD
2
Small molecule
Investigational
Unknown
Unknown
Acute Lung Injury; Arthritis, Rheumatoid; Coronary Disease; Neuralgia; Pulmonary Disease, Chronic Obstructive
MAP kinase p38 alpha inhibitor
DILMAPIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
Q3238VQW0N
Molecule Type:
Small molecule
Molecular Formula:
C23H19F3N4O3
Molecular Weight:
456.42
AlogP:
2.94
PSA:
100.27
HBD:
3.0
HBA:
#RotB:
6.0
Source:
RO6927005
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
RO6927005
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BUCELIPASE ALFA
2
Enzyme
Investigational
Unknown
Unknown
Premature Birth
Unknown
BUCELIPASE ALFA
×
Maximum Phase:
2
First Approval:
None
UNII:
3C617U1K19
Molecule Type:
Enzyme
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XRP9881
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
XRP9881
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZN-C3
2
Unknown
Investigational
Unknown
Unknown
Neoplasms; Osteosarcoma
Unknown
ZN-C3
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BASMISANIL
2
Small molecule
Investigational
Unknown
Unknown
Down Syndrome; Schizophrenia; Stroke
Unknown
BASMISANIL
×
Maximum Phase:
2
First Approval:
None
UNII:
788PET5SUA
Molecule Type:
Small molecule
Molecular Formula:
C21H20FN3O5S
Molecular Weight:
445.47
AlogP:
2.63
PSA:
102.6
HBD:
0.0
HBA:
#RotB:
5.0
Source:
DE-104
2
Small molecule
Investigational
Unknown
Unknown
Glaucoma, Open-Angle; Ocular Hypertension
Rho-associated protein kinase inhibitor
DE-104
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK3117391
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GSK3117391
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ECHINACEA PURPUREA, POWDERED
2
Unknown
Investigational
Unknown
Unknown
HIV Infections; Infections
Unknown
ECHINACEA PURPUREA, POWDERED
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
F16IL2
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Merkel Cell
Tenascin other
F16IL2
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
O-(2-FLUOROETHYL)-L-TYROSINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
O-(2-FLUOROETHYL)-L-TYROSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
P6VBV68WPV
Molecule Type:
Small molecule
Molecular Formula:
C11H14FNO3
Molecular Weight:
227.24
AlogP:
0.99
PSA:
72.55
HBD:
2.0
HBA:
#RotB:
6.0
Source:
DB959
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Peroxisome proliferator-activated receptor delta agonist
DB959
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CERLAPIRDINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Serotonin 6 (5-HT6) receptor antagonist
CERLAPIRDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
EK40PJ0V49
Molecule Type:
Small molecule
Molecular Formula:
C22H23N3O3S
Molecular Weight:
409.51
AlogP:
3.88
PSA:
75.29
HBD:
1.0
HBA:
#RotB:
7.0
Source:
GSK-256066
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic, Seasonal
Phosphodiesterase 4 inhibitor
GSK-256066
×
Maximum Phase:
2
First Approval:
None
UNII:
2D6GK059SR
Molecule Type:
Small molecule
Molecular Formula:
C27H26N4O5S
Molecular Weight:
518.6
AlogP:
3.93
PSA:
131.69
HBD:
2.0
HBA:
#RotB:
7.0
Source:
ETRUMADENANT
2
Unknown
Investigational
Unknown
Unknown
Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms
Adenosine A2a receptor antagonist
ETRUMADENANT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MPC-6827
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MPC-6827
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLUCOSAMINE SULFATE POTASSIUM CHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GLUCOSAMINE SULFATE POTASSIUM CHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
15VQ11I66N
Molecule Type:
Small molecule
Molecular Formula:
C12H28Cl2K2N2O14S
Molecular Weight:
605.53
AlogP:
-3.25
PSA:
116.17
HBD:
5.0
HBA:
#RotB:
1.0
Source:
MKC-1
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MKC-1
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
146
147
148
149
150
151
152
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA